Comparing the interaction models of the wild type and mutant proteins, we observed that specific mutations disrupt the interactions, such as between IL-10 and its receptor, IL-10 and A2M, and A2M and its partners, which may disrupt immune regulation in cancer. This evidence concerns the gene IL10 and cancer.